The stock of EyePoint Pharmaceuticals Inc (EYPT) has gone down by -15.66% for the week, with a -12.64% drop in the past month and a -15.55% drop in the past quarter. The volatility ratio for the week is 6.74%, and the volatility levels for the past 30 days are 5.98% for EYPT. The simple moving average for the past 20 days is -9.77% for EYPT’s stock, with a 21.41% simple moving average for the past 200 days.
Is It Worth Investing in EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Right Now?
Company’s 36-month beta value is 1.67.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EYPT is 46.63M, and currently, short sellers hold a 14.68% ratio of that floaft. The average trading volume of EYPT on April 18, 2024 was 925.92K shares.
EYPT) stock’s latest price update
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has experienced a decline in its stock price by -7.80 compared to its previous closing price of 20.94. However, the company has seen a fall of -15.66% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-07 that While the top- and bottom-line numbers for EyePoint Pharmaceuticals (EYPT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Analysts’ Opinion of EYPT
Many brokerage firms have already submitted their reports for EYPT stocks, with JP Morgan repeating the rating for EYPT by listing it as a “Overweight.” The predicted price for EYPT in the upcoming period, according to JP Morgan is $35 based on the research report published on January 22, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see EYPT reach a price target of $20. The rating they have provided for EYPT stocks is “Buy” according to the report published on November 02nd, 2023.
Robert W. Baird gave a rating of “Outperform” to EYPT, setting the target price at $33 in the report published on April 21st of the previous year.
EYPT Trading at -20.63% from the 50-Day Moving Average
After a stumble in the market that brought EYPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.70% of loss for the given period.
Volatility was left at 5.98%, however, over the last 30 days, the volatility rate increased by 6.74%, as shares sank -17.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.49% lower at present.
During the last 5 trading sessions, EYPT fell by -16.12%, which changed the moving average for the period of 200-days by +137.04% in comparison to the 20-day moving average, which settled at $21.19. In addition, EyePoint Pharmaceuticals Inc saw -16.46% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EYPT starting from Jones David Scott, who sale 209 shares at the price of $28.49 back on Feb 02 ’24. After this action, Jones David Scott now owns 37,962 shares of EyePoint Pharmaceuticals Inc, valued at $5,954 using the latest closing price.
Paggiarino Dario A., the Chief Medical Officer of EyePoint Pharmaceuticals Inc, sale 49,325 shares at $25.66 during a trade that took place back on Jan 26 ’24, which means that Paggiarino Dario A. is holding 36,505 shares at $1,265,539 based on the most recent closing price.
Stock Fundamentals for EYPT
Current profitability levels for the company are sitting at:
- -1.63 for the present operating margin
- 0.9 for the gross margin
The net margin for EyePoint Pharmaceuticals Inc stands at -1.55. The total capital return value is set at -0.26. Equity return is now at value -39.04, with -26.44 for asset returns.
Based on EyePoint Pharmaceuticals Inc (EYPT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 0.34. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -60.2.
Currently, EBITDA for the company is -73.2 million with net debt to EBITDA at 3.92. When we switch over and look at the enterprise to sales, we see a ratio of 14.58. The receivables turnover for the company is 57.17for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.45.
Conclusion
In a nutshell, EyePoint Pharmaceuticals Inc (EYPT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
